Loss-of-Function Polymorphic Variants of the Human Angiotensin II
... hypertension (Stankovic et al., 2003), aortic stiffness with age in hypertensive subjects (Lajemi et al., 2001), post-translational renal dysfunction and hypertension (Abdi et al., 2001), diabetic nephropathy (Doria et al., 1997; Antonellis et al., 2002), coronary artery vasoconstriction (Amant et a ...
... hypertension (Stankovic et al., 2003), aortic stiffness with age in hypertensive subjects (Lajemi et al., 2001), post-translational renal dysfunction and hypertension (Abdi et al., 2001), diabetic nephropathy (Doria et al., 1997; Antonellis et al., 2002), coronary artery vasoconstriction (Amant et a ...
- Wiley Online Library
... The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target ...
... The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target ...
conference on multiple hereditary exostoses abstract
... pressuring neighboring tissues. Several complications have been described with the most life threatening being the malignant transformation of an exostosis into a chrondrosarcoma. In the past ten years two EXT causing genes, EXT1 on chromosome 8q24 and EXT2 on chromosome 11p11-p12, have been identif ...
... pressuring neighboring tissues. Several complications have been described with the most life threatening being the malignant transformation of an exostosis into a chrondrosarcoma. In the past ten years two EXT causing genes, EXT1 on chromosome 8q24 and EXT2 on chromosome 11p11-p12, have been identif ...
Molecular Cloning and Pharmacological Characterization of a
... receptor (Tyr/Oct-Dro) (12, 13), the Locusta tyramine receptor (Tyr-Loc) (14), and the vertebrate a-adrenergic receptors. When only the TM regions are considered, overall identities are 50% (Tyr/Oct-Dro), 53% (Tyr-Loc), and ;40% (human a2-adrenergic receptors). A comparison of these amino acid seque ...
... receptor (Tyr/Oct-Dro) (12, 13), the Locusta tyramine receptor (Tyr-Loc) (14), and the vertebrate a-adrenergic receptors. When only the TM regions are considered, overall identities are 50% (Tyr/Oct-Dro), 53% (Tyr-Loc), and ;40% (human a2-adrenergic receptors). A comparison of these amino acid seque ...
Alternative splicing induced by nonsense mutations in the
... constructs that had the PTC in the VDJ exon. Compared to the alt-mRNA level in miniµ-wt, alt-mRNA levels are 18fold higher in miniµ-ter32, 15-fold higher in miniµ-ter73, and 80-fold higher in miniµ-ter57, respectively. The −1FS mutation increased alt-mRNA levels between 1.6- and 3-fold for miniµ-ter ...
... constructs that had the PTC in the VDJ exon. Compared to the alt-mRNA level in miniµ-wt, alt-mRNA levels are 18fold higher in miniµ-ter32, 15-fold higher in miniµ-ter73, and 80-fold higher in miniµ-ter57, respectively. The −1FS mutation increased alt-mRNA levels between 1.6- and 3-fold for miniµ-ter ...
Blood 93/6 - Semantic Scholar
... Properties of differentiated cells. The differentiation of M1 cells was assayed by measuring the induction of phagocytic activity in the cells. M1 cells (3 ⫻ 105 cells/mL) were incubated with cytokines for 2 days. The cells were harvested, suspended in serum-free medium containing 0.2% of a suspensi ...
... Properties of differentiated cells. The differentiation of M1 cells was assayed by measuring the induction of phagocytic activity in the cells. M1 cells (3 ⫻ 105 cells/mL) were incubated with cytokines for 2 days. The cells were harvested, suspended in serum-free medium containing 0.2% of a suspensi ...
Cross-species functional analyses reveal shared
... cerebral cortex was examined. In situ hybridization and immunohistochemistry for Sox11 was performed to characterize localization at different developmental ages (Fig. 1A-D; Fig. S1). Sox11 is preferentially expressed in the subplate, marginal zone, and cortical plate at embryonic day (E)14.5 and E1 ...
... cerebral cortex was examined. In situ hybridization and immunohistochemistry for Sox11 was performed to characterize localization at different developmental ages (Fig. 1A-D; Fig. S1). Sox11 is preferentially expressed in the subplate, marginal zone, and cortical plate at embryonic day (E)14.5 and E1 ...
beyond binding: molecular and cell biological approaches to
... the 5-HT2C receptor, which exists in variant forms determined by a posttranscriptional process called RNA editing (18). In many cases the functional significance of such variation among GPCRs is not known. However in some cases, such as RNA editing of the 5-HT2C receptor, individual receptor variant ...
... the 5-HT2C receptor, which exists in variant forms determined by a posttranscriptional process called RNA editing (18). In many cases the functional significance of such variation among GPCRs is not known. However in some cases, such as RNA editing of the 5-HT2C receptor, individual receptor variant ...
VLDL receptor
The very-low-density-lipoprotein receptor (VLDLR) is a transmembrane lipoprotein receptor of the low-density-lipoprotein (LDL) receptor family. VLDLR shows considerable homology with the members of this lineage. Discovered in 1992 by T. Yamamoto, VLDLR is widely distributed throughout the tissues of the body, including the heart, skeletal muscle, adipose tissue, and the brain, but is absent from the liver. This receptor has an important role in cholesterol uptake, metabolism of apoprotein-E-containing triacylglycerol-rich lipoproteins, and neuronal migration in the developing brain. In humans, VLDLR is encoded by the VLDLR gene. Mutations of this gene may lead to a variety of symptoms and diseases, which include type I lissencephaly, cerebellar hypoplasia, and atherosclerosis.